Literature DB >> 9523819

Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors.

V Y Hou1, C A Hirshman, C W Emala.   

Abstract

BACKGROUND: Neuromuscular relaxants such as pancuronium bind to M2 and M3 muscarinic receptors as antagonists. Blockade of muscarinic receptors in atria of the M2 subtype mediates tachycardia. In the lung, blockade of M2 receptors on parasympathetic nerves potentiates vagally induced bronchospasm, whereas blockade of M3 receptors on bronchial smooth muscle inhibits bronchospasm. The current study was designed to quantify the affinity of a series of neuromuscular relaxants for the M2 and M3 muscarinic receptors, which were individually stably transfected in Chinese hamster ovary cell lines.
METHODS: Competitive radioligand binding assays determined the relative binding affinities of the neuromuscular relaxants pancuronium, succinylcholine, mivacurium, doxacurium, atracurium, rocuronium, gallamine, and pipecuronium for the muscarinic receptor in the presence of a muscarinic receptor antagonist (3H-QNB) in membranes prepared from cells individually expressing either the M2 or M3 muscarinic receptor.
RESULTS: All muscle relaxants evaluated displaced 3H-QNB from muscarinic receptors. The relative order of potency for the M2 muscarinic receptor (highest to lowest) was pancuronium, gallamine, rocuronium, atracurium, pipecuronium, doxacurium, mivacurium, and succinylcholine. The relative order of potency for the M3 muscarinic receptor (highest to lowest) was pancuronium, atracurium, pipecuronium, rocuronium, mivacurium, gallamine, succinylcholine, and doxacurium.
CONCLUSIONS: All neuromuscular relaxants studied had affinities for the M2 and M3 muscarinic receptor, but only pancuronium and gallamine had affinities within the range of concentrations achieved with clinical use. The high affinities of gallamine and pancuronium for the M2 muscarinic receptor are consistent with a mechanism of M2 receptor blockade in relaxant-induced tachycardia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523819     DOI: 10.1097/00000542-199803000-00026

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  5 in total

Review 1.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs.

Authors:  Hiroshi Sunaga; Yi Zhang; John J Savarese; Charles W Emala
Journal:  Anesthesiology       Date:  2010-04       Impact factor: 7.892

3.  Neuromuscular nicotinic receptors mediate bladder contractions following bladder reinnervation with somatic to autonomic nerve transfer after decentralization by spinal root transection.

Authors:  Sandra M Gomez-Amaya; Mary F Barbe; Neil S Lamarre; Justin M Brown; Alan S Braverman; Michael R Ruggieri
Journal:  J Urol       Date:  2014-10-16       Impact factor: 7.450

4.  Supramolecular therapeutics to treat the side effects induced by a depolarizing neuromuscular blocking agent.

Authors:  Xiangjun Zhang; Qian Cheng; Lanlan Li; Liqing Shangguan; Chenwen Li; Shengke Li; Feihe Huang; Jianxiang Zhang; Ruibing Wang
Journal:  Theranostics       Date:  2019-05-18       Impact factor: 11.556

5.  Effects of muscle relaxants on ischaemia damage in skeletal muscle.

Authors:  Thomas Ledowski; Simone Nißler; Manuel Wenk; Esther M Pogatzki-Zahn; Daniel Segelcke
Journal:  Sci Rep       Date:  2018-04-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.